ProShare Advisors LLC Boosts Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

ProShare Advisors LLC grew its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 31.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,281 shares of the biopharmaceutical company’s stock after purchasing an additional 4,350 shares during the quarter. ProShare Advisors LLC’s holdings in Sage Therapeutics were worth $99,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. SG Americas Securities LLC lifted its stake in Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 8,228 shares during the last quarter. Empowered Funds LLC purchased a new position in Sage Therapeutics in the fourth quarter worth approximately $91,000. Ieq Capital LLC purchased a new position in Sage Therapeutics in the fourth quarter worth approximately $57,000. US Bancorp DE lifted its stake in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 2,268 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Sage Therapeutics by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock worth $2,510,000 after acquiring an additional 10,116 shares during the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Bank of America assumed coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price objective on the stock. Canaccord Genuity Group cut their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, February 12th. HC Wainwright reissued a “neutral” rating and set a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Scotiabank cut their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.87.

Sage Therapeutics Trading Down 1.4%

Shares of SAGE opened at $6.53 on Wednesday. The business’s 50-day moving average price is $7.07 and its 200 day moving average price is $6.77. The stock has a market capitalization of $408.92 million, a P/E ratio of -0.99 and a beta of 0.20. Sage Therapeutics, Inc. has a 1-year low of $4.62 and a 1-year high of $13.47.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the previous year, the business posted ($1.80) earnings per share. The company’s revenue was up 78.0% compared to the same quarter last year. On average, research analysts predict that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.